Epaminurad: A Promising hURAT1 Inhibitor for Effective and Safe Gout Management – Insights from a Phase 2b Dose-Finding Trial
Epaminurad significantly lowers serum urate levels in gout patients with excellent safety, offering a promising alternative to existing therapies. This randomized controlled trial identifies optimal dosing and confirms tolerability over 12 weeks.